Compass Pathways (NASDAQ:CMPS) Price Target Raised to $70.00 at HC Wainwright

Key Points

• HC Wainwright raised its target on Compass Pathways from $40 to $70 and maintained a "buy" rating, marking a notable bullish outlier among analysts.
• The Street consensus averages a $22.13 price target (1 Strong Buy, 6 Buy, 1 Hold, 1 Sell) while CMPS trades near $6.90 (down 5.9%), underscoring a large gap between analyst targets and the market price.
• Compass Pathways is a clinical‑stage biotech developing COMP360 psilocybin therapy for treatment‑resistant depression, with its flagship Phase IIb program having received Breakthrough Therapy designation.

Compass Pathways (NASDAQ:CMPS - Get Free Report) had its target price boosted by equities research analysts at HC Wainwright from $40.00 to $70.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock.

A number of other equities analysts have also issued reports on CMPS. Royal Bank Of Canada upped their target price on Compass Pathways from $21.00 to $22.00 and gave the company an "outperform" rating in a research report on Wednesday, February 18th. Compass Point set a $15.00 price target on Compass Pathways in a research report on Thursday, February 12th. Canaccord Genuity Group boosted their target price on shares of Compass Pathways from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Wednesday, February 18th. Weiss Ratings restated a "sell (d-)" rating on shares of Compass Pathways in a research note on Wednesday, January 21st. Finally, Lifesci Capital upgraded Compass Pathways to a "strong-buy" rating in a research report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $22.13.

Compass Pathways Stock Down 5.9%

Shares of NASDAQ:CMPS opened at $6.90 on Monday. The company has a 50 day moving average of $6.97 and a two-hundred day moving average of $6.08. The company has a market capitalization of $662.54 million, a price-to-earnings ratio of -2.54 and a beta of 1.90. Compass Pathways has a 52-week low of $2.25 and a 52-week high of $8.90. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.55.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Persistent Asset Partners Ltd acquired a new position in Compass Pathways during the fourth quarter worth $38,000. Advisory Services Network LLC bought a new position in Compass Pathways during the third quarter worth $41,000. China Universal Asset Management Co. Ltd. raised its position in shares of Compass Pathways by 46.7% during the second quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company's stock valued at $51,000 after buying an additional 5,817 shares during the last quarter. BIT Capital GmbH bought a new stake in shares of Compass Pathways in the 3rd quarter worth approximately $54,000. Finally, Northeast Financial Consultants Inc acquired a new stake in Compass Pathways during the second quarter worth $59,000. Institutional investors and hedge funds own 46.19% of the company's stock.

About Compass Pathways

Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.